BOOTS

Adults and children over 12 years Two 5ml doses every four to six hours up to a maximum of six doses in 24 hours as required. Children 6 to 12 years One 5ml dose every four to six hours up to a maximum of six doses in 24 hours as required.

5ml dose every four to six hours up to a maximum of six doses in 24 hours as required. 5ml dose twice a day up to a maximum of two doses in 24 hours as required. Children under 1 year Not recommended. Elderly The elderly are more likely to experience neurological anticholinergic effects.

g. a maximum of 12 mg in any 24 hours). Patients with renal or hepatic impairment should seek doctor’s advice prior to taking this medicine. (see section

The following convention has been utilised for the classification of the frequency of adverse reactions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000) and very rare (<1/10,000), not known (cannot be estimated from available data).

Adverse reactions identified during post-marketing use with chlorphenamine are listed below. g. increased energy, restlessness, nervousness) Glycerol may cause headache, stomach upset and diarrhoea. Sodium benzoate is a mild irritant to the skin, eyes and mucous membranes.

It may increase the risk of jaundice in newborn babies. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

). For oral administration. Do not exceed the stated the stated dose or frequency of dosing. The minimum interval between the doses should be 4 hours. 3 Contraindications Acute asthma, hypersensitivity to any of the ingredients or other antihistamines.

Premature infants or neonates because of their increased susceptibility to the antimuscarinic effects. This medicine should not be given to patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such treatment.

4 Special warnings and precautions for use This medicine should be given with caution to patients with epilepsy, severe cardiovascular disorders, liver disorders, renal impairment, glaucoma, urinary retention, prostatic enlargement, pyloroduodenal obstruction, asthma, bronchitis, bronchiectasis, thyrotoxicosis and severe hypertension.

g. Increased energy, restlessness, nervousness). Avoid use in elderly patients with confusion. The anticholinergic properties of chlorphenamine may cause drowsiness, dizziness, blurred vision and psychomotor impairment in some patients which may seriously affect ability to drive and use machinery.

The effects of alcohol may be increased and therefore concurrent use should be avoided. If symptoms do not go away within 5 days talk to your pharmacist or doctor. Keep all medicines out of the reach and sight of children. Although most antihistamines should be avoided by patients with porphyria, chlorpheniramine maleate has been used and is thought to be safe.

Should not be used with other antihistamine containing products, including antihistamine containing cough and cold medicines. Concurrent use with drugs which cause sedation such as anxiolytics and hypnotics may cause an increase in sedative effects, therefore medical advice should be sought before taking chlorphenamine concurrently with these medicines.

Information about some of the ingredients in this medicine This medicine contains maltitol liquid. Patients with rare hereditary problems of fructose intolerance should not take this. May have a mild laxative effect. 3 kcal/g maltitol.

Acute asthma, hypersensitivity to any of the ingredients or other antihistamines. Premature infants or neonates because of their increased susceptibility to the antimuscarinic effects. This medicine should not be given to patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such treatment.